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Abstract:  
Quiescent stem cells in adult tissues can be activated for homeostasis or repair. Neural stem cells 
(NSCs) in Drosophila are reactivated from quiescence in response to nutrition by the insulin 
signalling pathway. It is widely accepted that quiescent stem cells are arrested in G0. In this 
study, however, we demonstrate that quiescent NSCs (qNSCs) are arrested in either G2 or G0. 
G2/G0 heterogeneity directs NSC behavior: G2 qNSCs reactivate before G0 qNSCs. In addition, 
we show that the evolutionarily conserved pseudokinase Tribbles (Trbl) induces G2 NSCs to 
enter quiescence by promoting degradation of Cdc25String and subsequently maintains quiescence 
by inhibiting Akt activation. Insulin signalling overrides repression of Akt and silences trbl 
transcription, allowing NSCs to exit quiescence. Our results have implications for identifying 
and manipulating quiescent stem cells for regenerative purposes. 
 
One Sentence Summary:  
G2-arrested quiescent stem cells reactivate more readily than G0 cells and are regulated by the 
pseudokinase Tribbles.  
As in mammals, NSCs in Drosophila proliferate during embryogenesis, become quiescent in the 
late embryo and then proliferate again (reactivate) post-embryonically to produce neurons and 
glia (Fig. 1A) (1, 2). A nutritional stimulus induces reactivation (3); specifically, dietary amino 
acids induce glial cells in the blood brain barrier to secrete insulin/IGF-like peptides (dILPs) (4, 
5). dILPs activate the insulin signalling pathway in neighboring qNSCs, prompting them to exit 
quiescence (4, 6).  
 
Quiescent stem cells are widely accepted to be arrested in G0, a poorly-understood state 
characterised by a 2n DNA content and a lack of expression of cell cycle progression factors (7). 
We assessed whether Drosophila qNSCs are G0-arrested (Fig. S1A). As expected, we did not 
detect the M phase marker phospho-Histone H3 (pH3) in qNSCs (Fig. S1B). Previous studies 
demonstrated that qNSCs do not express the G1 marker Cyclin E, or incorporate the S phase 
markers BrdU/EdU (1, 3, 6, 8). However, we found that 73% of quiescent NSCs express the G2 
markers Cyclin A (CycA) and Cyclin B (CycB) (Figs. 1B, S1C). This suggests that (i) most 
qNSCs arrest in G2 and that (ii) qNSCs arrest heterogeneously in the cell cycle. 
 
We verified that ~75% of qNSCs are G2-arrested by comparing the FUCCI/pH3 profiles of 
qNSCs and proliferating NSCs (Figs. 1C-D, S1D) (9, 10). CycA+ qNSCs had twice the DNA 
content (Fig. 1E) and larger nuclei (30.5±0.66µm3 vs 18.1±0.32µm3, n=10 tVNCs, ~75 NSCs 
each) when compared to CycA- qNSCs. Thus qNSCs exhibit two types of stem cell quiescence: 
the majority arrests in G2 and a minority in G0 (Fig. 1F). G2 quiescence has not been reported 
previously in stem cells in mammals or Drosophila. 
 The choice of G2 or G0 arrest could be stochastic or pre-programmed. We found 7 G0 qNSCs in 
the T1 hemi-segment and 8 G0 qNSCs each in T2 and T3. A consistent subset of qNSCs always 
arrested in G0, namely NB2-2, NB2-4, NB2-5, NB3-4, NB5-3 and NB7-4 (Figs. 2A-B, S2A-F, 
Table S1). Of these, NB2-4 disappears from T1 during embryogenesis (11, 12), explaining why 
fewer qNSCs are G0-arrested in T1 than T2/T3. NB5-4/NB5-7 were G2-arrested in 50% of 
hemi-segments but did not always arrest in the same cell cycle phase either side of the midline 
(Fig. S2F). We conclude that, with the exception of NB5-4 and NB5-7, the choice of G2 or G0 
quiescence is entirely invariant. 
 
Is G2/G0 heterogeneity in qNSCs significant? We assessed reactivation of G2 and G0 qNSCs by 
tracking expression of the reactivation marker worniu (wor) (Figs. S3A-C). Over 86% of G2 
qNSCs reactivated by 20 hours after larval hatching (ALH), as compared to 20% of G0 qNSCs 
(Fig. 2C, n=10 tVNCs, ~150 NSCs each). For example NB3-4, a G0 qNSC, reactivated in fewer 
than 7% of hemi-segments (n=10 tVNCs, 6 hemi-segments each) (Fig. 2D). All NSCs 
reactivated by 48 hours ALH (Fig. S3C). Thus G2 qNSCs are faster-reactivating stem cells than 
G0 qNSCs.  
 
We next profiled gene expression in qNSCs using Targeted DamID (TaDa) (13), identifying 
1656 genes with GO terms including ‘nervous system development’ (35 genes, corrected p 
value: 2.70x10-6) and ‘neuroblast (NSC) development’ (10 genes, corrected p value: 8.40x10-4) 
(Tables S2 and S3). To identify quiescence-specific genes, we eliminated genes common to 
quiescent and proliferating NSCs (13) such as deadpan (dpn) (Figs. S4A-B). tribbles (trbl) is one 
of the most significantly expressed protein-coding genes specific to qNSCs (Fig. S4C). trbl 
encodes an evolutionarily conserved pseudokinase with three human homologues that have been 
implicated in insulin and MAPK signalling (reviewed by (14)). We confirmed that trbl labels 
quiescent but not proliferating NSCs in vivo (Figs. 3A, S4D-F). To date, no other gene has been 
identified that labels qNSCs specifically. 
 
trbl is necessary for quiescence entry, as NSCs continued to divide during late embryogenesis in 
trbl hypomorphic mutants or when trbl was knocked down specifically in NSCs (Figs. 3B, S5A-
D). trbl regulates quiescence entry specifically, without affecting division mode or cell viability 
(Fig. S5E-F). The ectopically dividing NSCs in the trblEP3519 mutant were G2, not G0, qNSCs 
(Fig. S5G). G2, but not G0, qNSCs also became significantly smaller in trblEP3519 mutants (Figs. 
S5H-J). As embryonic NSCs do not re-grow between cell divisions (15), the size reduction is 
consistent with excessive divisions. Consistent with a function in G2 quiescence, Trbl was 
expressed primarily in G2 qNSCs (Figs. 3C, S5K). 
 
Trbl is also required to maintain quiescence. RNAi-mediated knockdown of trbl in qNSCs 
caused NSCs to leave quiescence and divide (Fig. S5L-M). We generated transgenic flies 
carrying UAS-GFP-Trbl and drove expression with grainyhead (grh)-GAL4 (4) to assess 
whether Trbl is sufficient to maintain G2 quiescence. grh-GAL4 expression initiates at 
quiescence entry and is expressed in ~67% of NSCs, allowing comparison between neighboring 
GFP-Trbl-expressing and non-expressing NSCs. Almost all GFP-Trbl-expressing NSCs 
remained in G2 quiescence and expressed CycA (91.8±0.88%, n=10 tVNCs, ~120 NSCs each) 
(Figs. 3D-E, S6A-C). GFP-Trbl-expressing NSCs retained the primary process that is extended 
specifically by quiescent NSCs (see Fig. 1A), unlike control NSCs, which had begun to divide 
(Figs. S6B-C) (1, 4, 16). Thus Trbl is sufficient to maintain G2 quiescence. 
 
In the embryonic mesoderm, trbl induces G2 arrest by promoting Cdc25String protein degradation 
(17-19). We found that Cdc25String protein is reduced in NSCs at quiescence entry whereas 
cdc25string mRNA is maintained (Fig. 4A). Therefore, Cdc25String is regulated post-
transcriptionally at quiescence entry. Significantly more NSCs were Cdc25String protein-positive 
in trblEP3519 mutants (Figs. 4B, S7A-B). This increase in Cdc25String is sufficient to explain the 
excessive NSC proliferation in trbl mutants (Figs. S7C-D). Thus Trbl initiates quiescence entry 
by promoting Cdc25String protein degradation during late embryogenesis. 
 
Trbl also maintains NSC quiescence post-embryonically, however, it must act through another 
mechanism as Cdc25String is no longer expressed in post-embryonic qNSCs (Fig. S8A). Trbl is 
known to inhibit insulin signalling through binding Akt and preventing its phosphorylation (Fig. 
S8B) (20). Consistent with this, Trbl-expressing NSCs had less p4E-BP than control NSCs (Fig. 
S8C). If Trbl inhibits Akt to maintain quiescence, constitutively active Akt (myr-Akt (21); 
AktACT) should rescue Trbl-induced quiescence: AktACT fully rescued NSC reactivation (Figs. 
4C, S8D). In contrast, as Trbl is thought to act downstream of PI3K (20), constitutively active 
PI3K (dp110CAAX, (22); PI3KACT) should not rescue reactivation, which it did not (Figs. 4D, 
S8D). Thus Trbl maintains quiescence by blocking activation of Akt. This role is specific to 
post-embryonic NSCs since embryonic NSCs do not depend on insulin signalling to proliferate 
(Fig. S8E). 
 trbl expression must be repressed to allow NSC reactivation. We found that insulin signalling is 
necessary and sufficient to repress trbl transcription. NSCs misexpressing PTEN, an insulin 
pathway inhibitor, failed to down-regulate trbl transcription (Fig. S8F). In contrast, activating 
the insulin pathway by expressing AktACT in NSCs was sufficient to switch off trbl transcription 
(Fig. S8G).  
 
Here we have discovered the mechanisms by which Drosophila NSCs enter, remain in, and exit 
quiescence in response to nutrition (Fig. 4E). Trbl pseudokinase (1) promotes degradation of 
Cdc25String protein to induce quiescence, (2) blocks insulin signalling by inhibiting Akt in the 
same NSCs to maintain quiescence, and (3) is overridden by nutrition-dependent secretion of 
dILPs from blood-brain barrier glia, which activate insulin signalling in qNSCs, repress trbl 
expression and enable reactivation. 
 
Contrary to the prevailing dogma, we found that qNSCs are pre-programmed to arrest in G2 or 
G0. G2 qNSCs reactivate earlier and generate neurons before G0 qNSCs; this may ensure that 
neurons form the correct circuits in the appropriate order during brain development. G2 arrest 
also enables high fidelity homologous recombination-mediated repair in response to DNA 
damage, preserving genomic integrity during quiescence. Quiescent stem cells in mammals may 
also arrest in G2, with implications for isolating and manipulating quiescent stem cells for 
therapeutic purposes. 
  
References and Notes: 
1. J. W. Truman, M. Bate, Developmental Biology. 125, 145–157 (1988). 
2. A. Prokop, G. M. Technau, Development (1991). 
3. J. S. Britton, B. A. Edgar, Development. 125, 2149–2158 (1998). 
4. J. M. Chell, A. H. Brand, Cell. 143, 1161–1173 (2010). 
5. P. Spéder, A. H. Brand, Developmental Cell. 30, 309–321 (2014). 
6. R. Sousa-Nunes, L. L. Yee, A. P. Gould, Nature. 471, 508–512 (2011). 
7. T. H. Cheung, T. A. Rando, Nat. Rev. Mol. Cell Biol. 14, 329–340 (2013). 
8. S.-L. Lai, C. Q. Doe, eLife. 3 (2014), doi:10.7554/eLife.03363. 
9. A. Sakaue-Sawano et al., Cell. 132, 487–498 (2008). 
10. N. Zielke et al., Cell Rep. 7, 588–598 (2014). 
11. J. W. Truman, H. Schuppe, D. Shepherd, D. W. Williams, Development. 131, 5167–5184 
(2004). 
12. H. Lacin, J. W. Truman, K. VijayRaghavan, eLife. 5, e13399 (2016). 
13. T. D. Southall et al., Developmental Cell. 26, 101–112 (2013). 
14. P. A. Eyers, K. Keeshan, N. Kannan, Trends Cell Biol. (2016), 
doi:10.1016/j.tcb.2016.11.002. 
15. V. Hartenstein, E. Rudloff, J. A. C. Ortega, Roux's Arch Dev Biol. 196, 473–485 (1987). 
16. K. Narbonne-Reveau et al., eLife. 5, e13463 (2016). 
17. J. Mata, S. Curado, A. Ephrussi, P. Rørth, Cell. 101, 511–522 (2000). 
18. J. Grosshans, E. Wieschaus, Cell. 101, 523–531 (2000). 
19. T. C. Seher, M. Leptin, Curr. Biol. 10, 623–629 (2000). 
20. R. Das, Z. Sebo, L. Pence, L. L. Dobens, PLoS ONE. 9, e109530 (2014). 
21. J. S. Britton, W. K. Lockwood, L. Li, S. M. Cohen, B. A. Edgar, Developmental Cell. 2, 
239–249 (2002). 
22. S. J. Leevers, D. Weinkove, L. K. MacDougall, E. Hafen, M. D. Waterfield, EMBO J. 15, 
6584–6594 (1996). 
23. J. A. Campos-Ortega, V. Hartenstein, The Embryonic Origin of Drosophila melanogaster 
(1985). 
24. A. T. Quiñones-Coello et al., Genetics. 175, 1089–1104 (2007). 
25. P. Rørth et al., Development. 125, 1049–1057 (1998). 
26. S. Nagarkar-Jaiswal et al., eLife. 4, e05338 (2015). 
27. R. Albertson, C. Chabu, A. Sheehan, C. Q. Doe, J. Cell. Sci. 117, 6061–6070 (2004). 
28. L. Luo, Y. J. Liao, L. Y. Jan, Y. N. Jan, Genes & Development. 8, 1787–1802 (1994). 
29. T. Lee, L. Luo, Neuron. 22, 451–461 (1999). 
30. S. E. McGuire, P. T. Le, A. J. Osborn, K. Matsumoto, R. L. Davis, Science. 302, 1765–
1768 (2003). 
31. H. Huang et al., Development. 126, 5365–5372 (1999). 
32. A. Estacio-Gómez et al., Development. 140, 2139–2148 (2013). 
33. H.-H. Li et al., Cell Rep. 8, 897–908 (2014). 
34. S. Di Talia et al., Curr. Biol. 23, 127–132 (2013). 
35. W. G. Whitfield, C. Gonzalez, G. Maldonado-Codina, D. M. Glover, EMBO J. 9, 2563–
2572 (1990). 
36. R. Dittrich, T. Bossing, A. P. Gould, G. M. Technau, J. Urban, Development. 124, 2515–
2525 (1997). 
37. D. Kosman, S. Small, J. Reinitz, Dev. Genes Evol. 208, 290–294 (1998). 
38. T. Isshiki, M. Takeichi, A. Nose, Development. 124, 3099–3109 (1997). 
39. S. Rozen, H. Skaletsky, Methods Mol. Biol. 132, 365–386 (2000). 
40. K. H. Cox, D. V. DeLeon, L. M. Angerer, R. C. Angerer, Developmental Biology. 101, 
485–502 (1984). 
41. G. S. Wilkie, A. W. Shermoen, P. H. O'Farrell, I. Davis, Curr. Biol. 9, 1263–1266 (1999). 
 
 
 
Acknowledgments: 
We thank P. Callaerts, F. Díaz-Benjumea, J. Dods, C. Q. Doe, B. Edgar, E. Higginbotham, Y. 
Kimata, J. Ng, J. Urban, U. Walldorf, E. Wieschaus, Bloomington Drosophila Stock Centre and 
Developmental Studies Hybridoma Bank (DSHB) for generously providing reagents; T. Southall 
and O. J. Marshall for updating the TaDa microarray data to Release 6 of the Drosophila genome 
and for gene expression analysis; F. Doetsch, A. C. Delgado, F. J. Livesey, D. St. Johnston and 
the Brand laboratory members for discussion. Funding: This work was funded by the Royal 
Society Darwin Trust Research Professorship, Wellcome Trust Senior Investigator Award 
103792 and Wellcome Trust Programme grant 092545 to A.H.B., and Wellcome Trust PhD 
Studentship 097423 to L.O. A.H.B acknowledges core funding to the Gurdon Institute from the 
Wellcome Trust (092096) and CRUK (C6946/A14492). Author contributions: L.O. and A.H.B. 
designed the experiments, analysed the data and wrote the manuscript. L.O. performed the 
experiments. Competing interests: The authors declare no conflict of interest. Data and Materials 
accessibility: Microarray data have been deposited with GEO: accession GSE81745. 
 
  
Supplementary Materials: 
Materials and Methods 
Figures S1-S8 
Tables S1 
References (23-41) 
Additional data tables S2-S3 (separate files) 
  
C
G1
S
G2
M
Cell cycle 
assessment
pH
3
FUCCI
/G0
0ALH
10μm
B
Dpn   CycA
G2 phaseA
?
24 hrs
Quiescence
G0?
E
Pe
rc
en
ta
ge
 o
f N
SC
s
30
40
10
20
0
DAPI fluorescence / A.U.
0 4321
CycA+
CycA-
F
~25%
“G0”
~75%
G2
CycA/B+
2X DNA
Larger nuclei
CycA/B-
1X DNA
Smaller nuclei
D FUCCI during quiescence
10μm
0ALH
G2
pH3
G2
G2
G2
G2
100%80604020
G0 G2 ?
0
Reactivation
120 hrs
Proliferation
(post-embryonic)
24 hrs
Proliferation
(embryonic)
10μm Dpn   CycA
A
G0 qNSCs G2 qNSCs
2-2
2-1 1-1
1-2
3-1
MN
3-4
2-4
2-5
4-4
5-45-3
7-4
5-2
6-1 7-1
4-1
2-3
3-3 3-5
4-3
3-2
4-2
5-7
7-2 6-2
B
C D NB3-4 (G0 qNSC)
Eg  Wor  Dpn10μm Wor
20ALH
G0 G2
G0 vs G2 reactivation
0 8 12 16 204
W
or
+  N
SC
s 
/ %
100
80
60
40
20
0
G2
G0***
***
*** ***
Hours after larval hatching
20μm EdU20μm GFP-Trbl  Dpn  EdU
A
5μm
Emb13Before
quiescence
trbl reporter Dpn
trbl transcription
5μm trbl reporter Dpn
0ALHDuring
quiescence
5μm trbl reporter Dpn
48ALH
fed
After
reactivation
B
P
ro
lif
er
at
in
g
 (
p
H
3/
E
d
U
+)
 N
S
C
s 
/ %
trblEP3519
***80
60
40
20
0
CT
RL
MU
TA
NT
C Trbl protein
G2 G2
G2G0
Dpn Trbl GFSTF5μm
0ALHDuring quiescence
E
D GFP-Trbl
Q
u
ie
sc
en
t 
(p
H
3-
 E
d
U
-)
 N
S
C
s 
/ % - +100
80
60
40
20
0
***
24ALH, 29oC
GFP-Trbl in a subset of NSCs
A Before quiescence
20μm
20μm
Emb13
Cdc25String prot. Dpn
3215%
cdc25string mRNA
Emb13
20μm Cdc25String prot. Dpn
Quiescence entry
20μm
Emb15
130%
cdc25string mRNA
Emb15
20μm Cdc25String prot. Dpn
During quiescence
20μm
Emb1
002%
cdc25string mRNA
Emb1
E
Trbl Trbl
Cdc25String 
protein
Cdc25String 
protein
Akt
Trbl
Akt,nsulin 
signalling
dILPs
Proliferation Quiescence Proliferation
B
Cd
c2
5S
tri
ng
 p
ro
te
in
+ 
N
S
C
s 
at
 E
m
b
1
 / 
%
trblEP3519
1
1
10
12
8
6

0
2
***
CT
RL
MU
TA
NT
C
GFP 
control
Trbl
Trbl 
AktACT
Q
u
ie
sc
en
t 
(p
H
3-
 E
d
U
-)
 N
S
C
s 
/ %
100
80
60
0
20
0
ns
Trbl - ANt epistasis
***
D
GFP 
control
Trbl
Trbl 
P,3.ACT
Q
u
ie
sc
en
t 
(p
H
3-
 E
d
U
-)
 N
S
C
s 
/ %
100
80
60
0
20
0
Trbl - P,3. epistasis
***
***
Figure Legends: 
 
Fig. 1. qNSCs arrest in G0 or G2.  
(A) qNSCs are smaller than proliferating NSCs and extend a primary process, which is retracted 
upon activation from quiescence. Proliferating NSCs in the embryo do not exhibit a primary 
process prior to entering quiescence.  
(B) 73±0.79% of qNSCs (green) are CycA+ (red). n=10 tVNCs, ~150 NSCs each. 
(C) Cell cycle phase assessment using FUCCI and pH3. 
(D) Percentages of NSCs (outlined) in each cell cycle phase during quiescence. Colours as in 
(C). n=5 tVNCs, ~150 NSCs each. ?: undetermined.  
(E) DAPI intensities of CycA+ and CycA- qNSC nuclei are significantly different (p=2.20x10-16, 
Kolgomorov-Smirnov test). n=10 tVNCs, ~75 NSCs each. A.U.: arbitrary units. 1 A.U.: mean 
DAPI intensity of the CycA- population. Error bars indicate S.E.M. 
(F) Features of G2 and G0 qNSCs.  
Images are single section confocal images, unless indicated otherwise, and anterior is up in this 
and all subsequent figures.   
Fig. 2. G2 qNSCs reactivate before G0 qNSCs.  
(A) Maximum intensity projection of a tVNC hemi-segment, stained for G2 (yellow) and G0 
(green; circled) qNSCs. Dotted lines indicate hemi-segment boundaries. 
(B) Positions and identities of G0 qNSCs (green) within a hemi-segment. Dotted line represents 
the midline. Schematic modified from (12).  
(C) Quantification of Wor+ G0 or G2 qNSCs. n=10 tVNCs/time point, ~150 NSCs each. ***: 
p<1.39x10-5, two-tailed paired t-tests. Red lines indicate medians. 
(D) NB3-4 (Eg+; arrowed), remains small and Wor-negative at 20ALH, while neighbouring G2 
qNSCs have reactivated. 
 
  
Fig. 3. trbl regulates G2 qNSCs. 
(A) trbl reporter expression (green) in NSCs (red) before, during and after quiescence.  
(B) Quantification of proliferating NSCs in control (n=10) vs trblEP3519 mutant (n=8) tVNCs, 
with ~120 NSCs each. ***: p=7.06x10-14, Student’s t-test.  
(C) Trbl protein expression (green) in G2 (CycA+) or G0 (CycA-) qNSCs (red). 
(D) Quantification of qNSCs in grh-GAL4>GFP-Trbl tVNCs. “-” and “+” denote GFP-Trbl- and 
GFP-Trbl+ NSCs respectively. n=9 tVNCs, ~150 NSCs each. ***: p=3.90x10-4, Wilcoxon 
signed-rank test.  
(E) In grh-GAL4>GFP-Trbl brains, GFP-Trbl+ NSCs (green outlines) do not incorporate EdU, 
while control NSCs (yellow arrowheads) do.  
Red lines indicate medians. 
Fig. 4. Trbl induces and maintains quiescence through different mechanisms. 
(A) Top row: Cdc25String protein (green) expression in NSCs (red) before and during quiescence 
(percentages are mean±SEM). n=10 tVNCs/time point, ~130 NSCs each. Maximum intensity 
projections. Bottom row: In situ hybridisation against cdc25string mRNA at the same stages. 
(B) Percentages of Cdc25String protein+ NSCs in control (trblEP3519 heterozygote) vs mutant  
tVNCs. n=10 tVNCs/genotype, ~110 NSCs each. ***: p=9.08x10-5, Kolgomorov-Smirnov test. 
(C and D) Quantification of qNSCs in epistasis experiments between GFP-Trbl and AktACT (C) 
or PI3KACT
 
(D). n>10 tVNCs/condition, ~80 NSCs each. ***: p<3.39x10-9. ns: p>0.05, one way 
ANOVA followed by post-hoc Tukey’s HSD test. In (D), there is no significant difference 
between GFP-Trbl alone and GFP-Trbl+PI3KACT. 
(E) Three-step model for Trbl activity.  
Red lines indicate medians.  
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Materials and Methods 
 
Fly stocks and husbandry 
Drosophila melanogaster were reared in cages at 25oC, unless indicated otherwise. 
Embryos were collected onto yeasted apple juice plates and staged according to (23). For 
larval experiments, larvae were transferred to a fresh, yeasted food plate within 1 hour of 
hatching (designated 0ALH) and allowed to develop to the desired stage. To assess for 
trbl reporter expression under amino acid-deficient conditions, newly hatched larvae 
were instead transferred to a solution of 20% sucrose in PBS (3). The following stocks 
were used: w1118, FlyTrap Line YD0837 (trbl reporter) (24), trblEP1119 and trblEP3519 (25), 
trbl GFSTF (26), UASt-GFP-Trbl (this study), wor-GAL4 (27), inscMZ1407-GAL4 (28), 
grh-GAL4 (4), P{TRiP.HMJ02089}attP40 (UAS-trbl-RNAi, Bloomington Drosophila 
stock centre #42523), UASt-GFP-E2F11-230#26, UASt-mRFP1-NLS-CycB1-266#17 (FUCCI) 
(10), UAS-mCD8-GFP (29), UAS-myr-Akt (21), UAS-dp110CAAX (22), UAS-LT3-
NDam and UAS-LT3-NDam-RpII215 (13), tub-GAL80ts (30), UAS-dPTEN (31), UAS-
cdc25-RNAi (Vienna Drosophila Resource Center #330033). For identification of G0-
arrested NSCs, the following GAL4/split GAL4 combinations were used: ems-GAL4 
(32), R49C03, R18B03AD-R16H11DBD, R86D02, R19B03AD-R18F07DBD, R19B03AD-
R45D04DBD (Janelia FlyLight library, (33)). 
 
Immunostaining 
Embryos were dechorionated in 50% bleach/water for 3 minutes, fixed in 4% 
formaldehyde/PBS and heptane on a rolling shaker for 20 minutes and washed and stored 
in methanol at -20oC until use. For staining, fixed embryos were washed with 0.3% 
Triton X-100 (Sigma-Aldrich)/PBS (PBTx), blocked with 10% normal goat serum/PBTx 
and incubated with primary antibodies in PBTx overnight at 4oC. Antibodies were 
washed off with PBTx and replaced with secondary antibodies in PBTx for 2 hours at 
room temperature or overnight at 4oC. After washing, embryos were mounted in 70% 
glycerol/PBS. Larval brains were dissected in PBS, fixed in 4% formaldehyde/PBS for 20 
minutes, and processed as described for embryos. Larval brains were mounted in 
Vectashield mounting medium (Vector Laboratories). The following primary antisera 
were used: rabbit anti-Cdc25String 1:500 ((34)), rabbit anti-CycA 1:500 ((35), rb270), 
rabbit anti-CycB 1:500 ((35), rb271), guinea pig anti-Dpn 1:5,000 (kind gift of James 
Skeath), rat anti-Dpn 1:100 (abcam, 11D1BC7, ab195173), rabbit anti-Eg 1:500 (36), 
mouse anti-En 1:50 (DSHB, 4D9 conc.), rat anti-Ey 1:1,000 (kind gift of Patrick 
Callaerts), chick anti-GFP 1:2,000 (abcam, ab13970), rat anti-Mira 1:500 (kind gift of 
Chris Q. Doe), mouse anti-Pros 1:30 (DSHB, MR1A conc.), rabbit anti-phospho-Histone 
H3 Ser10 (pH3) 1:200 (Merck Millipore, 06-570), rat anti-Histone H3 phospho S28 
(pH3) 1:200 (abcam, ab10543), rabbit anti-phospho-4E-BP1 1:100 (Thr37/46, Cell 
Signaling Technology, 236B4), rabbit anti-Run 1:1,000 (kind gift of Eric Wieschaus), 
rabbit anti-Tll 1:200 ((37), 812), rabbit anti-Msh 1:500 (38), rat anti-Wor 1:100 (abcam, 
5A3AD2, ab196362). Primary antibodies were detected using Alexa Fluor-conjugated 
secondary antibodies (Life Technologies) diluted 1:500 in PBTx. For Cdc25String 
detection, embryos were pre-incubated for 1 hour in Image-iT FX signal enhancer 
solution (Thermo Fisher Scientific) as described in (34). 
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Region of interest 
Throughout this study, unless indicated otherwise, we assessed NSCs (identified by 
expression of the HES family gene deadpan (dpn)) in the thoracic segments of the ventral 
nerve cord (tVNC), a well-characterised region of the Drosophila central nervous system 
(Fig. S1A). 
 
Assessment of cell cycle phase using FUCCI/pH3 
wor-GAL4 was used to drive expression of UASt-GFP-E2F11-230#26, UASt-mRFP1-NLS-
CycB1-266#17 (FUCCI, (10)) in NSCs throughout development at 25oC. Larval brains were 
dissected at 0ALH for quiescent NSCs and 48ALH for reactivated NSCs and 
immunostained using anti-Dpn (NSC nuclei) and anti-pH3 (mitosis marker) antisera. The 
combination of FUCCI probes allows discrimination between G1 (GFP positive), S (RFP 
positive) and G2 and M (GFP/RFP double positive) phases. pH3 labelling marks M phase 
specifically.  
 
Assessment of DNA content using DAPI 
10 w1118 brains were dissected at 0ALH, immunostained using anti-CycA and anti-Dpn 
antisera and stained with DAPI for 2 hours at room temperature. Brains were imaged to a 
depth of 35µm from the ventral surface with a confocal microscope, at 1µm intervals. 
Dpn+ NSC nuclei were detected automatically using the “Measurement” function in 
Volocity software (Perkin Elmer). The DAPI intensities of CycA+ NSC nuclei (test, G2) 
were scaled to the mean DAPI intensity of CycA- NSC nuclei (control, G0) in the same 
brains.  
 
Identification of G0 qNSCs 
We identified each of the G0 qNSCs using the most recent descriptions and nomenclature 
published by Lacin and Truman (12). Each Drosophila NSC is named using Cartesian 
coordinates based on anterior-posterior and dorsal-ventral position during delamination 
from the neuroectoderm. 
 
Characterisation of wor as a reactivation marker 
Quiescent NSCs do not express wor at larval hatching (8), but expression is initiated in 
reactivating NSCs before they begin to divide. 100% of proliferating NSCs express wor 
by 48 hours ALH. Importantly, all dividing (pH3+) NSCs are Wor+ (n=75 NSCs, 10 
tVNCs). 
 
Transcriptional profiling of qNSCs 
In vivo transcriptional profiling was carried out using Targeted DamID (TaDa) (13). wor-
GAL4 was used to drive expression of UAS-LT3-NDam (“Dam-only”, reference) or UAS-
LT3-NDam-RpII215 (“PolII-Dam”, test) in NSCs. Unlike endogenous wor, wor-GAL4 is 
expressed in quiescent NSCs. GAL4 activity was temporally restricted to late 
embryogenesis and early larval stages using tub-GAL80ts to enrich for signal from 
qNSCs, although note that 10 non-quiescent NSCs/brain also express wor-GAL4 at these 
stages. Embryos were collected onto an apple juice plate for a 1 hour period and 
developed at 18oC for 28 hours until ~Stage 16. Embryos were shifted to 29oC for 10 
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hours to inactivate GAL80ts and induce expression of TaDa constructs. ~900 L1 larval 
brains were dissected for each condition. The TaDa protocol and analysis were carried 
out as described (13). Two replicates were performed and amplified DNA hybridised to a 
Nimblegen HX1 Drosophila whole genome tiling microarray corresponding to genome 
annotation release 5 (performed at FlyChip, Cambridge, UK). Microarray data was 
realigned to release 6 of the Drosophila melanogaster genome for analysis, using a 
modified version of the FlyBase dmel_r5_to_r6_converter.pl script. Genes were deemed 
as expressed above a log2 ratio of 0.585 and with a false discovery rate (FDR) value 
below 0.01. The expressed gene list is available in Table S2. 
 
In situ hybridisation against trbl and cdc25string mRNA 
Primers were designed in Primer3 (39) to amplify unique regions of trbl or cdc25string 
from an embryonic cDNA library, with an optimum length of 24bp and Tm of 60oC. 
Primers used were: 
 
trbl_FWD 5’-TAGTCAACTATTCGTCACCAGTCT-3’  
trbl_REV 5’-TTTTGCAATTTTCACTTACAAGAT-3’.  
cdc25string_FWD 5’-CTAAAATGCAATACTAGCCAAAAA-3’ 
cdc25string_REV 5’-CAATACGATAACACCCAAACTTAG-3’ 
 
To the 5’ ends of the REV primers were added the sequence 5’-
CAGTAATACGACTCACTATTA-3’ to allow in vitro transcription by T7 RNA 
polymerase (NEB). Approximately 1µg of amplified PCR product was used per gene for 
in vitro transcription with digoxigenin (DIG)-labelled nucleotides (NEB) for 72 hours at 
18oC. The transcribed products were degraded to an average length of 500bp using 
carbonate buffer (40), precipitated using ethanol and re-suspended in 10µl of DEPC water 
containing 0.2µl of RNAse inhibitor (Roche). DIG-labelled in situ probes were used at 
1:500 in hybridisation buffer (41). Hybridisations were performed as previously 
described (41), except that the hybridisation temperature was 65oC. Hybridised embryos 
were incubated with alkaline phosphatase (AP)-conjugated anti-digoxigenin (DIG) 
antibody (Roche), washed and signal detected through the chromogenic NBT/BCIP 
reaction. Embryos were mounted in 70% glycerol/PBS for imaging. cdc25string-hybridised 
embryos were filleted and prepared as flat preparations before imaging. 
 
RNAi-mediated knockdown of trbl in NSCs 
Flies carrying inscMZ1407-GAL4 (28) or grh-GAL4 were crossed to w1118 flies (control) or 
flies carrying P{TRiP.HMJ02089}attP40 (UAS-trbl-RNAi). Embryos were collected 
onto an apple juice plate for a 3 hour period at 25oC then developed at 29oC until stage 17 
embryogenesis or 5ALH respectively. Embryos or dissected brains were immunostained 
using anti-Dpn (NSC nuclei) and anti-pH3 (mitosis marker) antisera. The total mitotic 
index for each embryo was quantified by expressing the total number of pH3+ cells as a 
percentage of the number of NSC nuclei imaged in the same brain. 
 
Quantification of nuclear volume in trbl mutant larval brains 
10 control (trblEP3519 heterozygous) and 10 test (trblEP3519 homozygous) larval brains 
were dissected at 0ALH and immunostained using anti-Dpn and anti-CycA (G2 vs G0 
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assessment) antisera. Dpn staining was detected and quantified in three dimensions 
automatically using Volocity software (Perkin Elmer) to calculate nuclear volume.  
 
Generation of transgenic UAS-GFP-Trbl flies 
The trbl coding sequence was PCR amplified from an embryonic cDNA library and 
cloned into the pUASt-NmGFP6 vector (13) using NotI and XbaI sites to create an N-
terminal GFP fusion sequence. Transgenic flies were generated by germline injection of 
this construct into a w1118 background in the presence of the phiC31 integrase helper 
plasmid pBS130.  
 
EdU incorporation and detection 
Embryos: Embryos were collected onto an apple juice plate at 25oC, then dechorionated 
as normal in 50% bleach. After washing, embryos were air dried well in a nitex basket 
then incubated for 5 minutes in octane. After removal of octane, embryos were air dried 
briefly, then incubated for 30 minutes at room temperature in Schneider’s Drosophila 
medium (Gibco, 21720-024) containing EdU at 200µg/ml. Embryos were washed with 
heptane, then fixed as normal on a rolling shaker. EdU detection was performed using a 
Click-iT EdU Alexa Fluor 647 detection kit (Molecular Probes, C10340) according to the 
manufacturer’s instructions. Embryos were co-immunostained for Dpn (NSCs). 
 
Larvae: For grh-GAL4 experiments, larvae were reared as normal until 20ALH at 29oC. 
At this time, larvae were washed briefly in PBS and transferred to food plates containing 
EdU at 50µg/ml for a further 4 hours at 29oC until dissection. Following brain fixation, 
EdU detection was performed using a Click-iT EdU Alexa Fluor 647 detection kit 
according to the manufacturer’s instructions. Co-immunostaining with antibodies was 
performed as advised in the kit. Experiments with wor-GAL4 were conducted similarly, 
except that tub-GAL80ts was provided in the genetic background (designated worts). 
Embryos were reared at 18oC and larvae were shifted to 29oC at hatching to restrict 
GAL4 activity to quiescent stages. 
 
Image acquisition and processing 
Fluorescent images were acquired using a Leica SP8 confocal microscope and analysed 
using Volocity (Perkin Elmer) software. All images are single sections unless indicated 
otherwise. After in situ hybridisation, embryos were imaged by DIC on a Zeiss Axioplan 
microscope equipped with a Progres C10+ camera. Anterior is up in all images, unless 
indicated otherwise.  
 
Images were processed for brightness and contrast using Adobe Photoshop. Figures were 
compiled in Adobe Illustrator. 
 
Statistical analysis 
Data were arcsin-transformed before statistical analysis if they involved percentage data. 
Box and whisker plots depict median (red line), interquartile range (IQR, box) and 
1.5IQR below and above the first and third quartiles respectively (whiskers). 
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Fig. S1. 
 
 
 
Figure S1. Drosophila central nervous system anatomy and NSC quiescence. 
(A) The Drosophila central nervous system during embryonic (left) and post-embryonic 
(right) development, in ventral view. The nervous system is composed of two brain lobes 
(BL) and a ventral nerve cord (VNC, shaded). Red box indicates thoracic segments of the 
VNC (tVNC), which is the region quantified throughout this study. Mushroom body 
NSCs are a group of four NSCs per brain lobe that never become quiescent and act as an 
internal comparison. 
(B) 0% of qNSCs (green) are pH3+ (red). n=10 tVNCs, ~150 NSCs each. 
(C) 73±0.77% of qNSCs (green) are CycB+ (red). n=10 tVNCs, ~150 NSCs each. 
(D) Percentages of NSCs (outlined) in each cell cycle phase after reactivation. Colours as 
in (Fig. 1C). n=5 tVNCs, ~150 NSCs each. ?: undetermined.   
 
Images are single section confocal images and anterior is up in this, and all subsequent 
figures, unless indicated otherwise. 
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Fig. S2. 
 
 
 
Figure S2. Identifying G0 qNSCs.  
Identification of G0 qNSCs (yellow arrowheads), using diagnostic markers and GAL4 
drivers according to (12). GAL4 drivers were crossed to a reporter line carrying UAS-
mCD8-GFP to reveal expression.  
 
(A) NB2-2 is located medially, is Run+ and labels with ems-GAL4. ems-GAL4 exhibited 
variable expression; see Table S1 for details.   
(B) NB2-4 and NB2-5 are located dorsally and are part of the ‘dorsal triplet’, but do not 
label with R49C03-GAL4, which labels NB3-5 (asterisk).   
(C) NB3-4 is a small, Eg+ NSC that labels with R19B03AD-R16H11DBD.   
(D) NB5-3 is located in the En+ neuron file (blue). It is Ey+ (D-1) and Run+ (D-2), 
identifying it as NB5-3. R86D02-GAL4 labels the NB5-3 lineage, but not NB5-3 itself 
(D-3). 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(E) This CycA-negative NSC is En+ (E-1) and Msh+ (E-2), identifying it as NB7-4. It is 
also labelled specifically by R19B03AD-R18F07DBD (E-3). This GAL4 driver exhibited 
variable expression; see Table S1 for details.  
(F) NB5-4 and NB5-7 are Run-negative NSCs labelled by R19B03AD-R45D04DBD (Run 
staining not shown). Both NSCs are G0-arrested in 50% of hemi-segments. In the other 
50% of hemi-segments, one NSC is G0-arrested and the other is G2- arrested.  
 
NSC identities were confirmed in n=10 tVNCs, 3 hemi-segments each, except for NB5-
4/NB5-7 for which n=8 tVNCs. See also Table S1. 
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Fig. S3. 
 
 
 
Figure S3. Wor is a reactivation marker in NSCs 
(A) Quiescent NSCs (right) do not express Wor, in contrast to mushroom body NSCs 
(left) at the same developmental stage, which do not become quiescent (n=10 tVNCs). 
(B) NSCs (red) begin to express Wor (blue) during reactivation. White arrowhead 
indicates a reactivated, Wor+ NSC. At 12ALH, 27.5±1.2% of NSCs are Wor+. At 48ALH 
100% of NSCs are Wor+ (n=10 tVNCs/time point, ~150 NSCs each). 
(C) Quantification of Wor+ NSCs at 4 hour intervals during post-embryonic 
development. n=10 tVNCs/time point, ~150 NSCs each. 
 
Red lines indicate medians. 
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Fig. S4. 
 
 
 
Figure S4. Quiescent NSCs express trbl. 
(A) Comparison of coding genes expressed by quiescent NSCs (blue circle, this study) 
versus proliferating NSCs (white circle, (13)), assessed using TaDa.  
(B) RNA polymerase II occupancy at dpn locus in quiescent vs proliferating NSCs. Scale 
bars represent log2 ratio change between test and reference samples. Proliferating NSC 
data from (13). 
(C) RNA polymerase II occupancy at trbl locus in quiescent vs proliferating NSCs. Scale 
bars represent log2 ratio change between test and reference samples. Proliferating NSC 
data from (13). 
(D) In situ hybridisation against trbl mRNA before quiescence (left), at quiescence entry 
(centre) and during quiescence (right). Imaged by DIC; see methods for details. Anterior 
is up. 
(E) In animals starved of amino acids, NSCs remain quiescent until the animals are re-fed 
(3). 81.5±0.6% of NSCs express the trbl reporter at 48ALH in larvae fed an amino acid-
deficient diet, compared to 0% of NSCs in larvae fed with amino acids at the same 
developmental stage (see right panel of Fig. 3D).  n=10 tVNCs/condition, ~120 NSCs 
each. 
(F) Mushroom body NSCs (white asterisks and labelled by Tll (cyan)) do not become 
quiescent and do not express the trbl reporter (green). 
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Fig. S5. 
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Figure S5. trbl mutant NSCs divide excessively and become smaller.   
(A) Maximum intensity projections of control (trblEP3519 heterozygote) and trbl mutant 
(trblEP3519 homozygote) VNCs at embryonic stage 17, stained for the mitotic marker pH3 
(grayscale). 
(B) Quantification of dividing (pH3+) NSCs in control vs trblEP3519 mutant VNCs. n=10 
VNCs/genotype, ~225 NSCs each. ***: p=2.19x10-4, Mann-Whitney U test. 
(C) Quantification of dividing (pH3+) NSCs in trblEP1119 and trblEP1119/trblEP3519 mutant 
(MUT) VNCs at embryonic stage 17. Controls (CTRL) were heterozygous mutant 
embryos. n=10 VNCs/genotype, ~235 NSCs each. ***: p=2.72x10-7 (left) and 
p=5.11x10-7 (right), Student’s t-tests.  
(D) Quantification of mitotic cells in inscMZ1407-GAL4>w1118 (control) or trbl RNAi (test) 
VNCs at embryonic stage 17 at 29oC. trbl was knocked down in NSCs prior to normal 
quiescence entry. n=10 VNCs/genotype, ~230 NSCs each. **: p=1.43x10-3, Student’s t-
test.  
(E) Pros (green) and Mira (red) localisation in a dividing trblEP3519 mutant NSC (dotted 
outline). pH3 (cyan) shows division plane. A crescent of Pros/Mira is clearly visible.   
(F) Quantification of NSC number in control (trblEP3519 heterozgote) and trbl mutant 
(trblEP3519 homozygote) tVNCs at larval hatching. n=6 tVNCs/genotype. ns: p>0.05, 
Student’s t-test.   
(G) Percentage of dividing G0 or G2 qNSCs in control (CTRL, n=10) vs trblEP3519 mutant 
(MUT, n=10) tVNCs with 6 lineages each, at embryonic stage 17. NB2-4 and NB2-5 
were not distinguished. Data presented as mean±S.E.M. 
(H) Quantification of nuclear volume of G2 and G0 qNSCs in control vs trblEP3519 mutant 
tVNCs. n=9 tVNCs/genotype, ~75 NSCs each. ***: p=9.68x10-6, Student’s t-test. ns: 
p>0.05. 
(I and J) Comparison of NSC size in control (I) vs trblEP3519 mutant (J) tVNCs. Nuclei 
were visualised by immunostaining for Dpn (grayscale); G2 or G0 qNSCs were 
determined by staining for CycA (green). G2, but not G0, NSCs become smaller in trbl 
mutants.  
(K) Percentages of G2 and G0 quiescent NSCs expressing Trbl protein (Trbl-GFSTF is 
an epitope-tagged Trbl protein driven from its own locus (26)). n=7 tVNCs, ~120 NSCs 
each. ***: p=4.86x10-7, unequal variances t-test.  
(L and M) Conditional knockdown of trbl in NSCs that have already entered quiescence 
using grh-GAL4. Control NSCs (L) never divide. In trbl knockdown VNCs (M), NSCs 
leave quiescence and begin to divide (pH3, blue/grayscale, arrowhead, n=5/15 brains). 
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Fig. S6. 
 
 
 
Figure S6. Trbl is sufficient to maintain G2 quiescence.   
(A) GFP-Trbl misexpression strategy using grh-GAL4. Larvae were transferred to EdU-
containing food 4 hours prior to dissection. 
(B and C) grh-GAL4 was used to express GFP-Trbl (test, B) or mCD8-GFP (control, C) 
in NSCs. GFP-Trbl-expressing NSCs retain a primary process and divide less (pH3), 
while control NSCs are spherical and divide more. Note that pH3+ cells in (B) are NSCs 
that do not express GFP-Trbl. Maximum intensity projections. 
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Fig. S7. 
 
 
 
Figure S7. Trbl induces quiescence entry by decreasing Cdc25String protein.   
(A-B) Cdc25String protein abundance (green/grayscale) in control (trblEP3519 heterozygote) 
vs trblEP3519 mutant NSCs at embryonic stage 17. Control NSCs do not express Cdc25String 
protein after quiescence entry (B). In contrast, trblEP3519 mutant NSCs express Cdc25String 
protein (arrowheads, C). Maximum intensity projections. 
(C) Quantification of dividing (pH3+) NSCs in control tVNCs vs test tVNCs 
misexpressing Cdc25String at embryonic stage 17. inscMZ1407-GAL4 was used to 
misexpress Cdc25String in NSCs. n=10 tVNCs/genotype, ~120 NSCs each. ***: 
p=1.57x10-4, unequal variances t-test. 
(D) Quantification of dividing (pH3+) NSCs in control tVNCs vs cdc25string knockdown 
tVNCs at embryonic stage 15. wor-GAL4 was used to express cdc25string RNAi in NSCs. 
n=10 tVNCs/genotype, ~120 NSCs each. *: p=0.04, Student’s t-test. 
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Fig. S8. 
 
 
 
Figure S8. Reciprocal antagonism between Trbl and the insulin signalling 
pathway.   
(A) In situ hybridisation against cdc25string mRNA in the post-embryonic brain at 0ALH. 
Quiescent NSCs in the tVNC no longer transcribe cdc25string after hatching. Proliferative 
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mushroom body NSCs in the brain lobes (arrowheads) still transcribe cdc25string and act 
as an positive control for the probe. Imaged by DIC. 
(B) Trbl can bind and prevent Akt activation in the insulin signalling pathway (20).   
(C) GFP-Trbl (green) was expressed in a subset of NSCs (blue) using the grh-GAL4 
driver. Insulin/TOR pathway effector p4E-BP in red/grayscale. GFP-Trbl-expressing 
NSCs (arrowheads) have reduced p4E-BP staining compared to neighbouring control 
NSCs. 
(D) Epistasis experiments between GFP-Trbl and AktACT or PI3KACT. Maximum intensity 
projections of EdU incorporation (grayscale) in tVNCs. wor-GAL4 and tub-GAL80ts 
were used to express the indicated transgenes from larval hatching. AktACT, but not 
PI3KACT, rescues reactivation in GFP-Trbl-expressing NSCs.   
(E) Quantification of dividing (pH3+) NSCs in control vs test tVNCs misexpressing 
PTEN at embryonic stage 15. inscMZ1407-GAL4 was used to misexpress PTEN in NSCs. 
Reduced insulin signalling has no effect on embryonic NSC proliferation. n=10 
tVNCs/genotype, ~120 NSCs each. ns: p>0.05, two-tailed t-test. 
(F) In situ hybridisation against trbl mRNA in control brains (grh-GAL4 crossed to 
w1118) vs test brains (grh-GAL4 driving PTEN expression in NSCs). PTEN expression 
reduces insulin pathway activity and increases trbl transcription in the tVNC. Imaged by 
DIC. 
(G) In situ hybridisation against trbl mRNA in control brains (grh-GAL4 crossed to 
w1118) or test brains (grh-GAL4 driving AktACT expression in NSCs) under amino acid-
deficient conditions. Control NSCs (left) express trbl. AktACT expression (right) increases 
insulin pathway activity and downregulates trbl transcription in the tVNC. Imaged by 
DIC. 
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Table S1. 
 
G0 cell Diagnostic GAL4 drivers Molecular marker(s) Other features 
NB2-2 Labelled by ems-GAL4. This GAL4 driver 
labelled this NSC variably (~40% of hemi-
segments, n=10 brains, 3 hemi-segments 
each).   
Run+. Medial position, 
close to midline. 
NB2-4 Part of the ‘dorsal triplet’ of NSCs but not 
labelled by R49C03-GAL4. 
n/a. Dorsal position in 
tVNC; part of the 
‘dorsal triplet’. 
Absent in T1 hemi-
segment. 
NB2-5 Part of the ‘dorsal triplet’ of NSCs but not 
labelled by R49C03-GAL4. 
n/a. Dorsal position in 
tVNC; part of the 
‘dorsal triplet’.  
NB3-4 Labelled by R19B03AD-R16H11DBD. Eg+. Very small. 
NB5-3 Progeny are labelled by R86D02-GAL4. Ey+ Run+. Very small. 
NB5-4 Labelled by 19B03AD-45D04DBD and does not express Run. 
n=8 tVNCs. 
n/a. 
NB5-7 Labelled by 19B03AD-45D04DBD and does not express Run. 
n=8 tVNCs. 
n/a. 
NB7-4 Labelled by R19B03AD-18F07DBD. Every 
NSC labelled by this driver is G0-arrested. 
However, this driver does not label NB7-4 in 
every segment. 
En+ Msh+. n/a. 
 
Table S1. Features used to identify G0 qNSCs. 
All observations were confirmed in n=10 tVNCs, 3 hemi-segments each, unless indicated 
otherwise. NSCs were assessed at 0ALH. G0 qNSCs were defined as being Dpn+ CycA-
negative. 
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Additional Data  
Supplementary Table S2 (separate file) 
Genes expressed in quiescent NSCs. 
 
Supplemetary Table S3 (separate file) 
GO terms associated with quiescent NSC genes. 
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